2024
A systematic review on the efficacy of GLP-1 receptor agonists in mitigating psychotropic drug-related weight gain.
Menon T, Lee S, Gong X, Wong S, Le G, Kwan A, Teopiz K, Ho R, Cao B, Rhee T, Jing Zheng Y, Valentino K, Lin K, Vinberg M, Lo H, McIntyre R. A systematic review on the efficacy of GLP-1 receptor agonists in mitigating psychotropic drug-related weight gain. CNS Spectrums 2024, 1-7. PMID: 39582175, DOI: 10.1017/s1092852924000531.Peer-Reviewed Original ResearchPsychiatric medicationsEffects of GLP-1RAsReceptor agonistsEfficacy of GLP-1 receptor agonistsRandomized controlled trialsGLP-1RAsModerate weight changeMitigate weight gainPsychiatric populationsPsychotropic drugsCognitive processesWeight gainClinically meaningful effectGlucagon-like peptide-1 receptor agonistsPeptide-1 receptor agonistsGLP-1 receptor agonistsSystematic reviewPreliminary evidenceGlucose-lowering agentsLong-term safetyWeight changeMeaningful effectEfficacy profilePersonsAbnormal weightEfficacy of esketamine for perinatal depression: a systematic review and meta-analysis.
Wong S, Le G, Kwan A, Teopiz K, Rhee T, Ho R, Rosenblat J, Mansur R, McIntyre R. Efficacy of esketamine for perinatal depression: a systematic review and meta-analysis. CNS Spectrums 2024, 1-9. PMID: 39479775, DOI: 10.1017/s1092852924000452.Peer-Reviewed Original ResearchPostpartum depressionPerinatal depressionPrevention of postpartum depressionIncidence of postpartum depressionReduced health-related quality of lifeHealth-related quality of lifeSystematic reviewTreatment of postpartum depressionWeeks of childbirthMeta-analysisWeeks post-deliveryClinically meaningful implicationsQuality of lifeRandomized controlled trialsRandom-effects modelDecreased incidencePain managementPostpartum periodChildbirth laborIncidence ratePost-deliveryPsychosocial functioningEligibility criteriaControlled trialsPrimary outcomeElectroencephalography (EEG) spectral signatures of selective serotonin reuptake inhibitors (SSRIs), selective norepinephrine reuptake inhibitors (SNRIs) and vortioxetine in major depressive disorder: A systematic review
Le G, Wong S, Lu A, Vasudeva S, Gill H, Badulescu S, Portelles D, Zheng Y, Teopiz K, Meshkat S, Kwan A, Ho R, Rhee T, Rosenblat J, Mansur R, McIntyre R. Electroencephalography (EEG) spectral signatures of selective serotonin reuptake inhibitors (SSRIs), selective norepinephrine reuptake inhibitors (SNRIs) and vortioxetine in major depressive disorder: A systematic review. Journal Of Affective Disorders 2024, 368: 798-819. PMID: 39299586, DOI: 10.1016/j.jad.2024.09.081.Peer-Reviewed Original ResearchReuptake inhibitorsDepressive disorderPathophysiology of depressive disordersSystematic reviewAssociated with SSRIsClass of SSRIsNorepinephrine reuptake inhibitorsDoses of antidepressantsSerotonin reuptake inhibitorsFDA-approved agentsVortioxetine treatmentBlock reuptakeAntidepressant exposureSerotonin transporterSNRISSRIsVortioxetineDatabase inceptionConverging evidenceFunctional connectivitySerotoninNeural activityElectroencephalography signaturesStudy investigated changesInhibitorsAssociation between rumination, suicidal ideation and suicide attempts in persons with depressive and other mood disorders and healthy controls: A systematic review and meta-analysis
Le G, Wong S, Au H, Badulescu S, Gill H, Vasudeva S, Teopiz K, Rhee T, Ho R, Kwan A, Mansur R, Rosenblat J, McIntyre R. Association between rumination, suicidal ideation and suicide attempts in persons with depressive and other mood disorders and healthy controls: A systematic review and meta-analysis. Journal Of Affective Disorders 2024, 368: 513-527. PMID: 39303880, DOI: 10.1016/j.jad.2024.09.118.Peer-Reviewed Original ResearchSuicidal ideationMood disordersPsychiatric disordersLifetime history of suicide attemptsHealthy controlsHistory of suicide attemptsMeasures of ruminationSuicide attempt historyDiagnosed mood disorderTransdiagnostic associationsAttempt historyDepressive disorderNeurobiological substratesSuicide completersLifetime historyGeneral cognitionSuicide attemptsMeta-analysisIdeationSystematic reviewMoodClinically meaningful associationsSuicideResearch vistasFunctional impairmentPreclinical and clinical efficacy of kappa opioid receptor antagonists for depression: A systematic review
Wong S, Le G, Vasudeva S, Teopiz K, Phan L, Meshkat S, Kwan A, Rhee T, Ho R, Choi H, Cao B, Rosenblat J, McIntyre R. Preclinical and clinical efficacy of kappa opioid receptor antagonists for depression: A systematic review. Journal Of Affective Disorders 2024, 362: 816-827. PMID: 39019223, DOI: 10.1016/j.jad.2024.07.030.Peer-Reviewed Original ResearchMajor depressive disorderKappa-opioid receptorsKappa-opioid receptor antagonistConventional antidepressantsOpioid receptor antagonistReceptor antagonistMeasures of anhedoniaClinical trialsPhase 3 pivotal trialsEarly stages of clinical trialsMu-opioid receptorsPhase 3 studyClinically-relevant dosesStages of clinical trialsDepressive disorderSystematic reviewDepressive symptomsMu-opioidOpioid receptorsAntidepressantsAdjunctive therapyClinical efficacyAdverse eventsAticaprantResearch vistasComparing suicide completion rates in bipolar I versus bipolar II disorder: A systematic review and meta-analysis
Dev D, Le G, Kwan A, Wong S, Arulmozhi A, Ceban F, Teopiz K, Meshkat S, Rosenblat J, Guillen-Burgos H, Rhee T, Ho R, Cao B, d'Andrea G, Sundberg I, McIntyre R. Comparing suicide completion rates in bipolar I versus bipolar II disorder: A systematic review and meta-analysis. Journal Of Affective Disorders 2024, 361: 480-488. PMID: 38901691, DOI: 10.1016/j.jad.2024.06.045.Peer-Reviewed Original ResearchSuicide completion ratesCompletion ratesMeta-analysisSystematic reviewRisk of completed suicideHeterogeneity of studiesCompared to personsPooled odds ratioHigher mortality riskRate of completed suicideBipolar disorderIllness burdenPsychInfo databasesBD-IBD-IIMortality riskMortality hazardEligibility criteriaPRISMA guidelinesDisease burdenSuicide ratesLiterature searchSuicideBipolar disorder type IINon-significantNumber needed to treat (NNT) for ketamine and esketamine in adults with treatment-resistant depression: A systematic review and meta-analysis
Calder C, Kwan A, Teopiz K, Wong S, Rosenblat J, Mansur R, Rhee T, Ho R, Cao B, McIntyre R. Number needed to treat (NNT) for ketamine and esketamine in adults with treatment-resistant depression: A systematic review and meta-analysis. Journal Of Affective Disorders 2024, 356: 753-762. PMID: 38636712, DOI: 10.1016/j.jad.2024.04.039.Peer-Reviewed Original ResearchConceptsTreatment-resistant depressionKetamine treatmentRandomized controlled trialsUnipolar treatment-resistant depressionDefinition of treatment resistanceSystematic reviewBenefits of ketamineMeta-analysisHarm (NNHFunctional unblindingEsketamine treatmentPooled NNTNNH valuesPlacebo-controlledTreatment resistanceRacemic ketamineTherapeutic benefitLow riskNNTKetamineCalculate NNTsControlled trialsEsketamineTreat disordersClinical meaningfulnessEffects of cannabidiol and Δ9-tetrahydrocannabinol on cytochrome P450 enzymes: a systematic review
Smith S, Le G, Teopiz K, Kwan A, Rhee T, Ho R, Wu J, Cao B, Ceban F, McIntyre R. Effects of cannabidiol and Δ9-tetrahydrocannabinol on cytochrome P450 enzymes: a systematic review. Drug Metabolism Reviews 2024, 56: 164-174. PMID: 38655747, DOI: 10.1080/03602532.2024.2346767.Peer-Reviewed Original ResearchConceptsCannabinoid cannabidiolDrug-drug interactionsPsychotropic medicationsPsychotropic agentsCYP450 enzymesHigh risk of drug–drug interactionsInteraction of THCEffects of cannabidiolRisk of drug-drug interactionsInduction of CYP450 enzymesActivity of CYP450 enzymesIncreased adverse effectsPsychotropic drugsPlasma levelsClinical dataTHCClinical studiesClinicians evidenceCannabidiolHigh riskInduce cytochrome P450Clinical settingCannabisCytochrome P450 enzymesSystematic reviewSpectral signatures of psilocybin, lysergic acid diethylamide (LSD) and ketamine in healthy volunteers and persons with major depressive disorder and treatment-resistant depression: A systematic review
Le G, Wong S, Badulescu S, Au H, Di Vincenzo J, Gill H, Phan L, Rhee T, Ho R, Teopiz K, Kwan A, Rosenblat J, Mansur R, McIntyre R. Spectral signatures of psilocybin, lysergic acid diethylamide (LSD) and ketamine in healthy volunteers and persons with major depressive disorder and treatment-resistant depression: A systematic review. Journal Of Affective Disorders 2024, 355: 342-354. PMID: 38570038, DOI: 10.1016/j.jad.2024.03.165.Peer-Reviewed Original ResearchConceptsTreatment-resistant depressionLysergic acid diethylamideSerotonergic psychedelicsDepressive disorderHealthy controlsTheta powerHealthy volunteersBiomarkers predictive of responseGamma-band powerAssociated with increased theta powerSystematic reviewDissociative classDose of treatmentPredictive of responseClasses of agentsMood disordersBeta and delta bandsMDDAcid diethylamideMechanism of actionBiomarkers predictiveDepressionPatient populationModel of network connectivityResearch vistasEfficacy, safety, and tolerability of xanomeline for schizophrenia spectrum disorders: a systematic review
Leber A, Ramachandra R, Ceban F, Kwan A, Rhee T, Wu J, Cao B, Jawad M, Teopiz K, Ho R, Le G, Ramachandra D, McIntyre R. Efficacy, safety, and tolerability of xanomeline for schizophrenia spectrum disorders: a systematic review. Expert Opinion On Pharmacotherapy 2024, 25: 467-476. PMID: 38515004, DOI: 10.1080/14656566.2024.2334424.Peer-Reviewed Original ResearchPositive and Negative Syndrome ScalePANSS total score changeTotal score changeBaseline to week 5Randomized controlled trialsNegative Syndrome ScaleSchizophrenia spectrum disordersPlacebo groupScore changesSyndrome ScaleTreatment of adultsSpectrum disorderSchizophreniaXanomelineWeek 5Dry mouthClinical Trials RegistryTreatment avenuesPlaceboSide effectsPreclinical trialsTrials RegistryControlled trialsPRISMA guidelinesSystematic review
2023
Efficacy and safety of ketamine-assisted electroconvulsive therapy in major depressive episode: a systematic review and network meta-analysis
Rhee T, Shim S, Popp J, Trikalinos T, Rosenheck R, Kellner C, Seiner S, Espinoza R, Forester B, McIntyre R. Efficacy and safety of ketamine-assisted electroconvulsive therapy in major depressive episode: a systematic review and network meta-analysis. Molecular Psychiatry 2023, 29: 750-759. PMID: 38123725, DOI: 10.1038/s41380-023-02366-8.Peer-Reviewed Original ResearchMajor depressive episodeStandardized mean differenceElectroconvulsive therapyAnesthetic agentsDepressive symptomsDepressive episodeRelative riskDiagnosis of MDESystematic reviewKetamine-treated patientsSafety of ketamineSerious adverse eventsResultsTwenty-two studiesMethodsPubMed/MEDLINEImportant clinical considerationsRandom-effects modelCognitive performanceAdverse eventsAntidepressant efficacyECT useTrials RegistryClinical efficacyCochrane LibraryWorse outcomesPatient profilesDextromethorphan-Bupropion for the Treatment of Depression: A Systematic Review of Efficacy and Safety in Clinical Trials
Akbar D, Rhee T, Ceban F, Ho R, Teopiz K, Cao B, Subramaniapillai M, Kwan A, Rosenblat J, McIntyre R. Dextromethorphan-Bupropion for the Treatment of Depression: A Systematic Review of Efficacy and Safety in Clinical Trials. CNS Drugs 2023, 37: 867-881. PMID: 37792265, DOI: 10.1007/s40263-023-01032-5.Peer-Reviewed Original ResearchConceptsMajor depressive disorderPathophysiology of MDDSystematic reviewMontgomery-Åsberg Depression Rating ScaleNMDA receptor antagonist dextromethorphanTransient adverse eventsRisk of biasDepression Rating ScaleMonoamine-based antidepressantsTreatment of depressionBackgroundA significant proportionPlacebo control groupCombination of dextromethorphanMechanism of actionConclusionCurrent evidenceClinical remissionAdverse eventsCochrane riskBias toolDatabase inceptionTreatment optionsScore reductionClinical trialsDepressive disorderActive control groupGlucagon-like peptide 1 (GLP-1) receptor agonists as a protective factor for incident depression in patients with diabetes mellitus: A systematic review
Cooper D, Ramachandra R, Ceban F, Di Vincenzo J, Rhee T, Mansur R, Teopiz K, Gill H, Ho R, Cao B, Lui L, Jawad M, Arsenault J, Le G, Ramachandra D, Guo Z, McIntyre R. Glucagon-like peptide 1 (GLP-1) receptor agonists as a protective factor for incident depression in patients with diabetes mellitus: A systematic review. Journal Of Psychiatric Research 2023, 164: 80-89. PMID: 37331261, DOI: 10.1016/j.jpsychires.2023.05.041.Peer-Reviewed Original ResearchConceptsGLP-1 receptor agonistsGlucagon-like peptide-1 receptor agonistsPeptide-1 receptor agonistsIncident depressionDiabetes mellitusReceptor agonistType 2 diabetes mellitusRetrospective observational studyPubMed/MEDLINEEnglish-language articlesHigh interstudy heterogeneityGoogle Scholar databasesPaucity of literatureGlycemic controlNeuroprotective effectsAntidepressant propertiesNeuroprotective potentialInterstudy heterogeneityObservational studyPatientsSystematic reviewAgonistsMellitusScholar databasesProtective factorsEfficacy, safety, and tolerability of ulotaront (SEP-363856, a trace amine-associated receptor 1 agonist) for the treatment of schizophrenia and other mental disorders: a systematic review of preclinical and clinical trials
Le G, Gillissie E, Rhee T, Cao B, Alnefeesi Y, Guo Z, Di Vincenzo J, Jawad M, March A, Ramachandra R, Lui L, McIntyre R. Efficacy, safety, and tolerability of ulotaront (SEP-363856, a trace amine-associated receptor 1 agonist) for the treatment of schizophrenia and other mental disorders: a systematic review of preclinical and clinical trials. Expert Opinion On Investigational Drugs 2023, 32: 401-415. PMID: 37096491, DOI: 10.1080/13543784.2023.2206559.Peer-Reviewed Original ResearchConceptsTrace amine-associated receptor 1Long-term efficacyTreatment of schizophreniaClinical trialsSystematic reviewMental disordersNegative symptomsAdverse effectsAdverse effect profileCochrane Collaboration's toolRisk of biasInclusion/exclusion criteriaNovel therapeutic targetPubMed/MEDLINEQuality of lifeMechanism of actionAlternative treatment methodAtypical antipsychoticsEffect profileSimilar pathophysiologyCognitive dysfunctionPreclinical studiesExclusion criteriaOvid databasesTherapeutic targetCOVID-19 vaccination for the prevention and treatment of long COVID: A systematic review and meta-analysis
Ceban F, Kulzhabayeva D, Rodrigues N, Di Vincenzo J, Gill H, Subramaniapillai M, Lui L, Cao B, Mansur R, Ho R, Burke M, Rhee T, Rosenblat J, McIntyre R. COVID-19 vaccination for the prevention and treatment of long COVID: A systematic review and meta-analysis. Brain Behavior And Immunity 2023, 111: 211-229. PMID: 36990297, PMCID: PMC10067136, DOI: 10.1016/j.bbi.2023.03.022.Peer-Reviewed Original ResearchConceptsSARS-CoV-2 vaccinationLong COVIDCo-primary objectivesCOVID-19 vaccinationPublic health priorityLong-COVID patientsUnvaccinated patientsPersonal health decisionsVaccine doseMost patientsVaccination scheduleCOVID patientsHealth priorityProtective effectVaccinationSystematic reviewDifferential riskPatientsSystematic searchHealth decisionsCOVIDPreventionMeta-analytic resultsDose
2022
Biomarkers of ketamine's antidepressant effect: An umbrella review
Meshkat S, Ho R, Cao B, Teopiz K, Rosenblat J, Rhee T, Di Vincenzo J, Ceban F, Jawad M, McIntyre R. Biomarkers of ketamine's antidepressant effect: An umbrella review. Journal Of Affective Disorders 2022, 323: 598-606. PMID: 36521662, DOI: 10.1016/j.jad.2022.12.021.Peer-Reviewed Original ResearchConceptsKetamine's antidepressant effectsAntidepressant effectsUmbrella reviewMajor depressive disorder (MDD) pathogenesisRapid acting antidepressant (RAAD) effectsMechanistically relevant biomarkersPotential peripheral biomarkerTreatment-resistant patientsAnti-inflammatory effectsNMDA receptor antagonistReal-world populationTreatment response predictionInflammatory markersPeripheral biomarkersKetamine actionReceptor antagonistSymptom deteriorationClinical utilityNeuroimaging biomarkersDisorder pathogenesisSynaptic plasticityCingulate cortexSystematic reviewKetamineFunctional connectivityEfficacy and Safety of Ketamine vs Electroconvulsive Therapy Among Patients With Major Depressive Episode
Rhee TG, Shim SR, Forester BP, Nierenberg AA, McIntyre RS, Papakostas GI, Krystal JH, Sanacora G, Wilkinson ST. Efficacy and Safety of Ketamine vs Electroconvulsive Therapy Among Patients With Major Depressive Episode. JAMA Psychiatry 2022, 79: 1162-1172. PMID: 36260324, PMCID: PMC9582972, DOI: 10.1001/jamapsychiatry.2022.3352.Peer-Reviewed Original ResearchConceptsStandardized mean differenceMajor depressive episodeSerious adverse eventsElectroconvulsive therapyAdverse eventsDepressive episodeClinical trialsDepression severityEfficacy outcomesSystematic reviewUnique adverse effect profileMeta-analyses (PRISMA) reporting guidelinesSafety of ketamineAdverse effect profileData extractionEuropean clinical trialsDiagnosis of depressionModerate methodological qualityMedical Subject Headings termsPreferred Reporting ItemsCognition/memoryRandom-effects modelSubject Headings termsAcute phaseEffect profileKetamine use in pediatric depression: A systematic review
Meshkat S, Rosenblat J, Ho R, Rhee T, Cao B, Ceban F, Danayan K, Chisamore N, Vincenzo J, McIntyre R. Ketamine use in pediatric depression: A systematic review. Psychiatry Research 2022, 317: 114911. PMID: 37732856, DOI: 10.1016/j.psychres.2022.114911.Peer-Reviewed Original ResearchConceptsSafety of ketamineRandomized clinical trialsPediatric depressionIntravenous ketamineNon-competitive N-methyl-D-aspartate (NMDA) receptor antagonistN-methyl-D-aspartate receptor antagonistSystematic reviewOpen-label trialSevere adverse eventsCommon psychiatric disordersDifferent administration modalitiesAdverse eventsAntidepressant effectsSignificant morbidityMean ageCase reportReceptor antagonistClinical trialsAdministration modalitiesDepressive symptomsPsychiatric disordersKetamine useElectronic databasesLarger sample sizeKetamineIs legalization of recreational cannabis associated with levels of use and cannabis use disorder among youth in the United States? A rapid systematic review
O’Grady M, Iverson MG, Suleiman AO, Rhee TG. Is legalization of recreational cannabis associated with levels of use and cannabis use disorder among youth in the United States? A rapid systematic review. European Child & Adolescent Psychiatry 2022, 33: 701-723. PMID: 35508822, DOI: 10.1007/s00787-022-01994-9.Peer-Reviewed Original ResearchRapid systematic reviewPrevalence of cannabisYoung adultsSystematic reviewRecreational legalizationYoung Adults (CARDIA) studyRisk of biasDate of inceptionPubMed/MEDLINEFull-text articlesWeb of ScienceTreatment optionsAdult studiesTrip DatabaseMajority of studiesAppropriate preventionUse prevalencePrevalence measuresText articlesTheses GlobalPrevalenceCannabisAdolescent studiesRecreational cannabisAdults
2021
Prevalence of type 2 diabetes mellitus, impaired fasting glucose, general obesity, and abdominal obesity in patients with bipolar disorder: A systematic review and meta-analysis
Liu YK, Ling S, Lui LMW, Ceban F, Vinberg M, Kessing LV, Ho RC, Rhee TG, Gill H, Cao B, Mansur RB, Lee Y, Rosenblat J, Teopiz KM, McIntyre RS. Prevalence of type 2 diabetes mellitus, impaired fasting glucose, general obesity, and abdominal obesity in patients with bipolar disorder: A systematic review and meta-analysis. Journal Of Affective Disorders 2021, 300: 449-461. PMID: 34965395, DOI: 10.1016/j.jad.2021.12.110.Peer-Reviewed Original ResearchConceptsType 2 diabetes mellitusAbdominal obesityGeneral obesityNewcastle-Ottawa ScaleGender-matched controlsDiabetes mellitusBipolar disorderGender-matched healthy controlsPrevalence of T2DMRisk of obesityCase-control studyTimes greater riskPooled prevalenceLanguage restrictionsPlasma glucoseHealthy controlsHigh prevalenceSources of heterogeneityInclusion criteriaMethodological qualityObesityPatientsT2DMSystematic reviewGreater risk